National Institute for Health and Clinical Excellence [document type for example, IFP, QRG] on [topic] Document cover sheet Date Version Editor Action number 30/08/2017 1 NGC 1 2 NATIONAL INSTITUTE FOR HEALTH AND CARE 3 **EXCELLENCE** 4 **Guideline scope** 5 Persistent pain: assessment and 6 management 7 8 The Department of Health in England has asked NICE to develop a clinical 9 guideline on persistent pain. 10 The guideline will be developed using the methods and processes outlined in 11 Developing NICE guidelines: the manual. 12 This guideline will also be used to develop the NICE quality standard for 13 persistent pain.

NICE guideline: Persistent pain: draft scope for consultation (25 October to 22 November

2017)

14 **1** Why the guideline is needed

15 Persistent pain is often difficult to treat. There has been little change in the prevalence and time course of persistent pain despite significant scientific 16 17 advances to improve understanding of the neurobiology of pain. Pain is not a 18 well-defined disease entity with a predictable prognosis and response to 19 treatment. Persistent pain can be associated with many different types of 20 tissue injuries and disease processes. Sometimes no underlying disease 21 process can be found. Pain has a significant impact on individuals and their 22 families and carers. Pain affects mood, sleep, mobility, role within the family 23 and ability to work. Current mood, anxiety about pain, previous experience of 24 pain, and unpleasant life events not associated with pain can influence how 25 pain is perceived.

26 Key facts and figures

27 The prevalence of persistent pain has been difficult to define: a recent 28 systematic review identified prevalence estimates ranging from 8.7% to 29 64.4%, with a pooled mean of 31%. An earlier systematic review suggests 30 that persistent pain in the UK affects between one-third and one-half of the 31 population. There are few data to identify what proportion of people who 32 meet criteria for persistent pain either need or wish for medical intervention. 33 Almost half of people with persistent pain have a diagnosis of depression 34 and two-thirds of people are unable to work outside the home. Studies of 35 disability in relation to a number of medical conditions show that pain 36 contributed the most to disability measures.

Attempts to treat persistent pain are costly to the healthcare system. In
2016, £537 million was spent on prescribing analgesics, with at least an
additional 50% cost incurred from the prescription of other drug classes
such as antidepressants and antiepileptic drugs. Further healthcare costs
include visits to primary care, referrals to secondary care for medical
opinions (from pain specialists and other disciplines) and costs of
investigations and interventions, including surgery.

- The economic impact of pain is higher than for other medical conditions:
- 45 this relates to absenteeism, poor productivity and people with pain leaving
- the work force. The indirect (productivity) cost of back pain in the UK was

47 estimated to be between £5 billion and £10.7 billion.

Painful conditions such as arthritis and back pain account for one-third of
all claims for disability benefits in the UK.

50 Current practice

- There is no medical intervention, pharmacological or non-pharmacological,
- that is helpful for more than a minority of people and benefits of treatmentsare modest in terms of effect size and duration.
- Additional morbidity resulting from treatment is not unusual in this
 population, so it is important to evaluate the treatments we offer to people
 with persistent pain, to focus resources appropriately and to minimise
 iatrogenic harm.
- The complexity of persistent pain and the association with significant distress and disability can influence clinical interactions around pain.
- 60 People often expect a clear diagnosis and effective treatment but these are
- 61 rarely available. GPs and specialists in other fields find persistent pain as
- one of the most challenging conditions to manage and often have negative
- 63 perceptions of people with pain. This is despite the fact that in every field
- 64 there is a proportion of people with persistent pain. This can have important
- 65 consequences for the therapeutic relationship between healthcare
- 66 professionals and patients.
- A clear understanding of the evidence for effectiveness of persistent pain
- 68 treatments:
- 69 improves the confidence of healthcare professionals in their
- 70 conversations about pain and
- helps healthcare professionals and patients to have realistic
 expectations about outcomes of treatment.

73 **2** Who the guideline is for

- 74 People using services, their families and carers, and the public will be able to
- 75 use the guideline to find out more about what NICE recommends and help
- 76 them make decisions.
- 77 This guideline is for:
- healthcare professionals in all settings where NHS or local authority funded
- 79 care is provided
- 80 commissioners and providers of services
- people with persistent pain and their families and carers.
- 82 It may also be relevant for:
- employers
- third-sector organisations.
- 85 NICE guidelines cover health and care in England. Decisions on how they
- 86 apply in other UK countries are made by ministers in the Welsh Government,
- 87 <u>Scottish Government</u>, and <u>Northern Ireland Executive</u>.

88 Equality considerations

- 89 NICE has carried out an equality impact assessment [add hyperlink in final
- 90 version] during scoping. The assessment:
- lists equality issues identified and how they have been addressed
- explains why any groups are excluded from the scope.

93 **3** What the guideline will cover

94 **3.1** Who is the focus?

95 Groups that will be covered

- Adults (18 and older) with persistent pain.
- 97 People with a history of addiction (including dependency on prescription
- 98 drugs) have been identified as needing specific consideration.

99 Groups that will not be covered

• Children and young people (under 18) with persistent pain.

101 **3.2** Settings

102 Settings that will be covered

103 All settings in which NHS commissioned care is provided.

104 **3.3** Activities, services or aspects of care

105 Key areas that will be covered

- 106 We will look at evidence in the areas below when developing the guideline,
- 107 but it may not be possible to make recommendations in all the areas.
- 108 1 Assessment of persistent pain
- 109 Risk factors for long-term persistent pain.
- 110 Identification of co-existing mental health conditions, emotional problems
 111 and social problems related to the person's pain.
- 112 2 Management
- 113 Strategies to improve quality of life.
- 114 Pharmacological and non-pharmacological management of non-specific¹
- 115 persistent pain.
- Pain management programmes including pain self-management and
 peer-led programmes.
- 118
- 119 Note that guideline recommendations for medicines will normally fall within
- 120 licensed indications; exceptionally, and only if clearly supported by evidence,
- 121 use outside a licensed indication may be recommended. The guideline will
- 122 assume that prescribers will use a medicine's summary of product
- 123 characteristics to inform decisions made with individual people.

¹ The term 'non-specific' persistent pain is used here to include conditions that may be recorded as fibromyalgia, complex regional pain syndrome, myofascial pain, somatoform disorder, functional syndromes, chronic widespread pain, pelvic pain of unknown origin.

NICE guideline: Persistent pain: draft scope for consultation (25 October to 22 November 2017)

124	Are	eas that will not be covered
125	1	Specific management of pain covered by related NICE guidance:
126		endometriosis, headaches, irritable bowel syndrome, low back pain and
127		sciatica, rheumatoid arthritis, osteoarthritis and spondyloarthritis.
128	2	Pain management as part of palliative care.
129	Re	lated NICE guidance
130	•	Endometriosis: diagnosis and management (2017) NICE guideline NG73
131	•	Spondyloarthritis in over 16s: diagnosis and management (2017) NICE
132	9	guideline NG65
133	•	Neuropathic pain in adults: pharmacological management in non-specialist
134	1	<u>settings</u> (2017) NICE guideline CG173
135	•	Low back pain and sciatica in over 16s: assessment and management
136		(2016) NICE guideline NG59
137	•	Multimorbidity: clinical assessment and management (2016) NICE
138	9	guideline NG56
139	•	Palliative care for adults: strong opioids for pain relief (2016) NICE
140	9	guideline CG140
141	•	Controlled drugs: safe use and management (2016) NICE guideline NG46
142	•	Rheumatoid arthritis in adults: management (2015) NICE guideline CG79
143	•	Headaches in over 12s: diagnosis and management (2015) NICE guideline
144		CG150
145	•	Workplace health: management practices (2015) NICE guideline NG13
146	•	Osteoarthritis: care and management (2014) NICE guideline CG177
147	•	Common mental health problems: identification and pathways to care
148		(2011) NICE guideline CG123
149	•	Depression in adults with a chronic physical health problem: recognition
150	i	and management (2009) NICE guideline CG91
151	•	Depression in adults: recognition and management (2009) NICE guideline
152		CG90
153	•	Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy):
154		diagnosis and management (2007) NICE guideline CG53

155 • Post-traumatic stress disorder: management (2005) NICE guideline CG26

156 NICE guidance about the experience of people using NHS services

157 NICE has produced the following guidance on the experience of people using

- 158 the NHS. This guideline will not include additional recommendations on these
- 159 topics unless there are specific issues related to persistent pain:
- 160 <u>Medicines adherence</u> (2009) NICE guideline CG76
- Service user experience in adult mental health (2011) NICE guideline
 CG136
- 163 Patient experience in adult NHS services (2012) NICE guideline CG138
- 164 Medicines optimisation (2015) NICE guideline NG5
- 165 **3.4 Economic aspects**
- 166 We will take economic aspects into account when making recommendations.
- 167 We will develop an economic plan that states for each review question (or key
- area in the scope) whether economic considerations are relevant, and if so,
- 169 whether this is an area that should be prioritised for economic modelling and
- analysis. We will review the economic evidence and carry out economic
- 171 analyses, using an NHS and personal social services perspective, as
- 172 appropriate.

173 **3.5** *Key issues and questions*

174 While writing this scope, we have identified the following key issues and key

- 175 questions related to them:
- 176 **1** Assessment of persistent pain
- 177 Risk factors for long-term persistent pain
- 178 1.1 What risk factors affect the prognosis of people with persistent pain?
- 179 Identification of co-existing mental health conditions, emotional problems
 180 and social problems related to the person's pain.
- 181 1.2 Do co-existing mental health conditions or emotional problems
- 182 (related to pain) affect the prognosis of people with persistent pain?

183		1.3 Do co-existing social problems (related to pain) affect the prognosis
184		of people with persistent pain?
185		
186	2	Management
187	_	Strategies to improve quality of life
188		2.1 What is the clinical and cost effectiveness of strategies aimed at
189		improving the quality of life of people with persistent pain (for example,
190		sleep management, mobility, social engagement and confidence in
191		managing the condition)?
192	_	Pharmacological and non-pharmacological management of non-specific
193		persistent pain
194		2.2 What is the clinical and cost effectiveness of pharmacological
195		management of non-specific persistent pain?
196		2.3 What is the clinical and cost effectiveness of non-pharmacological
197		management for non-specific persistent pain?
198	_	Pain management programmes, including pain self-management and
199		peer-led programmes
200		2.4 What is the clinical and cost effectiveness of self-management
201		programmes for the management of persistent pain?
202		2.5 What is the clinical and cost effectiveness of peer-led programmes
203		for the management of persistent pain?
201	-	

- The key questions may be used to develop more detailed review questions,
- which guide the systematic review of the literature.
- 206 **3.6** *Main outcomes*


The main outcomes that will be considered when searching for and assessingthe evidence are:

- 209 1 Pain reduction
- 210 2 Health-related quality of life (for example, EQ-5D, SF36, SF12)
- 211 3 Function
- 212 4 Depression/anxiety
- 213 5 Adverse events

214 **4 NICE Pathways**

215 4.1 NICE Pathways

- 216 <u>NICE Pathways</u> bring together everything we have said on a topic in an
- 217 interactive flowchart. When this guideline is published, the recommendations
- will be included in the NICE Pathway on persistent pain (in development).
- 219 An outline based on this scope is included below. It will be adapted and more
- 220 detail added as the recommendations are written during guideline
- development.



222

5 Further information

This is the draft scope for consultation with registered stakeholders. The consultation dates are 25 October 2017 to 22 November 2017.

The guideline is expected to be published in January 2020.

You can follow progress of the <u>guideline</u>. Our website has information about how <u>NICE guidelines</u> are developed.

224